- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears New Version of AI Segmentation Software for Brain MRI
Offering rapid automated segmentation of brain structures, the ClearPoint 2.2 software reportedly enhances visualization for a variety of targeted, MRI-guided procedures.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled ClearPoint 2.2 software, which provides automated segmentation of brain structures from magnetic resonance imaging (MRI) scans.
ClearPoint Neuro, the manufacturer of the software, said it provides rapid segmentation that facilitates a variety of targeted, MRI-guided procedures ranging from deep brain stimulation to laser ablation.
Here one can see a comparison of the ClearPoint Maestro Brain Model (a) and the ClearPoint 2.2 software (b), which includes segmentation of subnuclei. (Images courtesy of NeuroImage.)
The ClearPoint 2.2 software also includes the Maestro Brain Model, which was recently validated in a study published in NeuroImage. In a quantitative reproducibility analysis, researchers found the combination of the shape-constrained deformable brain model and voxel-wise tissue segmentation was superior to manual expert segmentation.
“The ClearPoint system can now offer fast, peri-procedural segmentation of the cortical structures of the brain to identify both targets and safety zones for cell and gene therapy delivery, laser ablation, biopsy and deep brain stimulation,” noted Joe Burnett, the president and CEO of ClearPoint Neuro.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
